**Background:** Outbreaks of viral communicable disease and appearance of new viral strains can represent public health emergencies. As diagnostic laboratories and test developers design, manufacture and validate diagnostic assays to prepare for these threats, positive reference materials are needed. SeraCare has developed AccuPlex™ recombinant virus technology to produce whole process reference materials that mimic clinical samples. They are mammalian virus products and are non-infectious. AccuPlex technology was used to develop quality controls for amplified nucleic acid tests for the emerging viruses Ebola, Chikungunya, Dengue-2, Norovirus GII, MERS-CoV and Zika as well as drug resistant HIV-1. Here we demonstrate the performance of these quality control materials and show that they have an extended stability at 2--8 °C and do not require freezer storage.

**Methods:** AccuPlex™ controls for RNA viruses employ engineered Sindbis virus, and a portion of the Sindbis structural genes are replaced with up to ∼4000 bp of the diagnostic targets of interest. Where the diagnostic targets are well defined, those regions were incorporated into one recombinant virus. For example, the recombinant Chikungunya reference material contains portions of the NSP1, NSP2, NSP4, Capsid, E3 and E1 genes, and is based on the sequence of strain IND-06-Guj. The recombinant Dengue reference material contains portions of 3′ UTR, NSP5, Capsid, and E1 genes from serotype 2. Recombinant Norovirus, Ebola, and MERS-coV reference materials follow a similar design scheme.

However, when diagnostic targets are undefined, as is the case for Zika, a different design scheme is required. The entire Zika genome was divided into four segments and each segment was used to generate an AccuPlex recombinant virus. The Zika reference material therefore is a mixture of four distinct AccuPlex recombinant viruses. Dividing the pathogen\'s genome among multiple constructs ensures each recombinant virus is not functional. Additional safety features such as gene truncation, multiple stop codons and frame shifts are also used and the products are heat treated for viral inactivation.

**Results:** Recombinant AccuPlex viruses were diluted in defibrinated plasma or other commutable matrices and characterized by Digital PCR using pathogen specific primers and probes. The target concentration range of the reference materials is from 5E + 05 copies/mL for recombinant Ebola, to 5E + 06 copies/mL for many of the other viruses. Functional testing of the reference materials on Altona RealStar RT-PCR Kits as well as Primer Design Ltd GeneSig Advanced kits showed positive detection. The recombinant viruses gave cycle threshold values (Ct) on these assays consistent with a low positive control (Ct of 27--31.5). Accelerated stability studies indicate that the product is stable at 4 °C for at least two years. Real time stability data at Room Temperature has been collected through 20 months and updated stability data will be presented.

**Conclusions:** SeraCare has developed stable, well-characterized whole process controls for pathogenic viruses. These reference materials will enable laboratories to validate tests and train technicians to ensure preparedness for outbreaks. These products demonstrate the utility of recombinant virus technology to produce non-infectious controls for select agents and viruses difficult to source or propagate.
